Price$1.00+0.02 (+2.04%)
01:30 PM06:15 PM
News · 26 weeks46+50%
2025-11-022026-04-26
Mix1790d
- Other8(47%)
- SEC Filings6(35%)
- Insider3(18%)
Latest news
25 items- PRPositive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual MeetingAUSTIN, Texas, April 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract has been selected for publication at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29 – June 2, 2026 in Chicago, Illinois. The abstract details positive clinical data from studies of predictive biomarkers in patients receiving its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of lung cancer.
- SECGenprex Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene TherapyResearch on Biomarkers May Help Enrich Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials, Potentially Predicting Patient Response to REQORSA TreatmentDemonstrates Commitment to Tailored Treatment Options for Patients With Unmet Medical NeedAUSTIN, Texas, April 21, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company has entered into a new Sponsored Research Agreement (SRA) with The University of Texas MD Anderson Cancer Center (UT MD Anderson) to study biomarkers that may predict patient response to Reqorsa® Gene Th
- PRGenprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual MeetingTROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene TherapyREQORSA Induced Apoptosis and Decreased Tumor Volume in ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Cell Lines and In Vivo Mouse StudiesREQORSA Boosts Natural Killer (NK) Cell Antitumor Activity AUSTIN, Texas, April 20, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026 in San Diego, Californ
- SECSEC Form PRE 14A filed by Genprex Inc.PRE 14A - Genprex, Inc. (0001595248) (Filer)
- INSIDERSEC Form 4 filed by Longnecker Brent M4 - Genprex, Inc. (0001595248) (Issuer)
- SECSEC Form 10-K filed by Genprex Inc.10-K - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual MeetingResearch Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa® Gene TherapyREQORSA is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung CancerREQORSA Boosts Natural Killer (NK) Cell Antitumor Activity AUSTIN, Texas, March 18, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026 in San Diego, California. The collaborators
- PRGenprex to Participate at BIO Europe Spring 2026AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March 23-25, 2026 in Lisbon, Portugal. In attendance will be Ryan Confer, President and Chief Executive Officer at Genprex and Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex. Throug
- INSIDERChief Medical Officer Berger Mark Stanley covered exercise/tax liability with 7,168 shares, decreasing direct ownership by 25% to 21,692 units (SEC Form 4)4 - Genprex, Inc. (0001595248) (Issuer)
- INSIDERPresident, CEO and CFO Confer Ryan M. covered exercise/tax liability with 9,330 shares, decreasing direct ownership by 20% to 36,331 units (SEC Form 4)4 - Genprex, Inc. (0001595248) (Issuer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat CancerJapanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'sTecentriq® AUSTIN, Texas, Feb. 23, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies to treat cancer. Also, the European Patent Office has issued a Decision to Grant relating to a patent for the combination of REQORSA and PD-1 antibodies to treat cancer. Genprex
- PREGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsightThe EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat CancersPatent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq® Company Adds Additional Acclaim-3 Clinical Trial Site AUSTIN, Texas, Feb. 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that IP Australia, the Australian government agency responsible for administering Australia's intellectual property rights system, has issued a Notice of Acceptance, on February 5, 2026, of the Genprex patent application claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodie
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- SECSEC Form S-8 filed by Genprex Inc.S-8 - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Provides Clinical Update on Diabetes Gene Therapy ProgramCompany Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced a clinical program update on its diabetes gene therapy program for GPX-002, the Company's diabetes gene therapy drug candidate, detailing recent achievements and future advancements. This update follows the recent announcement of positive preliminary preclinical data from studies of GPX-002 in both mouse and non-human primate (NHP) models, specifica
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal StudiesPreliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human Primates GPX-002 Rejuvenated Exhausted Beta Cells and Normalized Glucose Levels in Type 2 Diabetic Mice AUSTIN, Texas, Jan. 6, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced preliminary in vivo preclinical proof-of-concept data for GPX-002, the Company's diabetes gene therapy drug candidate which may have the potential for long-term control of Type 1 diabetes (T1D) and Type 2 diabetes (T2D), in a
- INSIDERDirector Moreno Toscano Jose Antonio was granted 9,000 shares, increasing direct ownership by 5,732% to 9,157 units (SEC Form 4)4 - Genprex, Inc. (0001595248) (Issuer)
- INSIDERChief Medical Officer Berger Mark Stanley was granted 28,500 shares, increasing direct ownership by 7,917% to 28,860 units (SEC Form 4)4 - Genprex, Inc. (0001595248) (Issuer)